Trial
NCT03312114
Anti-PD-L1 and SAbR for Ovarian Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
AstraZeneca
Condition
Recurrent Epithelial Cancer of Ovary
Intervention
Avelumab
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-12